Loading
A phase 3 trial of Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine in follicular lymphoma, run by Kite, A Gilead Company, active and no longer recruiting.
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT05371093 by Kite, A Gilead Company, with 231 participants enrolled, started 2022-09-22 and due to reach its primary completion in 2030-10. Interventions recorded: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab. Conditions listed: Relapsed/Refractory Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenalidomide, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Lenalidomide, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Axicabtagene ciloleucel, Fludarabine, Follicular lymphoma, Cyclophosphamide.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide, CAR-T cell therapy.
Shares Lenalidomide, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Fludarabine, Gilead Sciences (incl. Kite), Cyclophosphamide.
Shares Fludarabine, Lenalidomide, Cyclophosphamide, CAR-T cell therapy.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/